AstraZeneca Receives Positive Agreement for AXANUM in Europe

AstraZeneca's AXANUM for prevention of cardiovascular events has received positive agreement for approval in 23 European Union member countries and in Norway.

AstraZeneca announced Tuesday that AXANUM, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway.

The EU decision took place under the decentralised procedure (DCP), with Germany acting as reference member state. This process is now followed by national approvals and local pricing and reimbursement discussions.

AXANUM is used for prevention of cardiovascular (CV) events such as heart attack or stroke, in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.

AXANUM is the only medicine that ensures every sing